Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease
A legfontosabb adatok
- Ki végzi
- Xuanwu Hospital, Beijing
- Hol
- Kína3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 160 fő, tervezett
- Kezdés
- 2026. okt.
- Várható befejezés
- 2027. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Active Personalized Intermittent Theta Burst Stimulation
- Sham Personalized Intermittent Theta Burst Stimulation
- A regiszteradat frissítve
- 2026. október 23.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with memory or thinking problems caused by cerebral small vessel disease, a disease of the brain's small blood vessels. It tests a magnetic brain stimulation called iTBS against a fake (sham) stimulation.
- Életkor
- 45 to 85 years
- Nem
- All sexes
- A betegség stádiuma
- Vascular mild cognitive impairment or mild vascular dementia, lasting at least three months. Brain MRI must show small vessel disease. MMSE score ≥18 and <28 (≥16 with primary school education), or CDR score of 0.5 or 1. mRS score ≤2. MTA score of 0-1. No stroke or mini-stroke (TIA) in the past three months.
- Korábbi kezelés
- No transcranial magnetic stimulation or other brain stimulation treatment in the past three months.
- Biomarker vagy leletérték
- Brain MRI showing small vessel disease, such as several small deep strokes, white matter changes with Fazekas score ≥2, tiny brain bleeds or enlarged spaces around blood vessels.
A részvétel fő kizáró okai
- Thinking problems mainly caused by another disease, such as Alzheimer's disease, Parkinson's disease or a brain tumor
- Severe depression, psychosis or other severe mental illness
- History of seizures, a close relative with epilepsy, or metal or electronic implants such as a pacemaker
- Cannot have an MRI, for example due to metal implants or fear of closed spaces
- Pregnancy, breastfeeding or plans to become pregnant
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Aged 45-85 years, of either sex
- Cognitive decline in memory or another cognitive domain, reported by the participant or an informant, lasting at least three months; brain MRI evidence of cerebral small vessel disease (CSVD); and a diagnosis of CSVD-related vascular cognitive impairment
- Vascular mild cognitive impairment or mild vascular dementia. Vascular mild cognitive impairment is defined as impairment in one or more cognitive domains with largely preserved independence in daily activities. Mild vascular dementia is defined as cognitive impairment that mildly affects instrumental activities of daily living or activities of daily living, while the participant remains able to complete study assessments and treatment
- Neuropsychological evidence of cognitive impairment: Mini-Mental State Examination (MMSE) score ≥18 and <28, with a lower threshold of ≥16 for participants with primary school education; Clinical Dementia Rating (CDR) score of 0.5 or 1; or cognitive impairment determined after adjustment for educational attainment
- Relatively stable overall functional status, with a modified Rankin Scale (mRS) score ≤2
- Brain MRI findings consistent with CSVD, meeting at least one of the following:
- Multiple supratentorial small subcortical infarcts, with or without white matter lesions
- Moderate-to-severe white matter hyperintensities, with a Fazekas score ≥2, with or without lacunar infarcts
- Other CSVD-related imaging findings, such as cerebral microbleeds or enlarged perivascular spaces
- No acute cerebrovascular event, including acute cerebral infarction, intracerebral hemorrhage, or transient ischemic attack, within the preceding three months
- No or only mild hippocampal/medial temporal lobe atrophy, with a medial temporal atrophy (MTA) score of 0-1
- Written informed consent voluntarily provided by the participant or their legally authorized representative
Ki nem vehet részt
- A contraindication to MRI or inability to complete MRI examinations, such as metal implants or claustrophobia
- Cognitive impairment primarily explained by another disease, including Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease-related cognitive impairment, normal pressure hydrocephalus, brain tumor, demyelinating disease, encephalitis, epilepsy, or severe traumatic brain injury
- Large cortical infarction, watershed infarction, strategic infarction, intracerebral hemorrhage, hydrocephalus, or another brain lesion sufficient to explain the cognitive impairment
- Severe depression, a psychotic disorder, or another severe psychiatric disorder
- Severe systemic disease or a metabolic abnormality that may cause cognitive impairment, such as severe hepatic or renal dysfunction, thyroid dysfunction, vitamin B12 or folate deficiency, severe anemia, or active infection
- A history of alcohol or drug abuse or dependence
- A contraindication to intermittent theta burst stimulation (iTBS), including a history of seizures, a first-degree relative with epilepsy, intracranial metal implants, a cardiac pacemaker, a cochlear implant, a deep brain stimulator, a vagus nerve stimulator, or another implanted electronic or metallic medical device
- Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation
- Impaired consciousness from any cause
- Transcranial magnetic stimulation or another neuromodulation treatment within the preceding three months
- Pregnancy, breastfeeding, or plans to become pregnant during the study
- Current participation in another interventional clinical study
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 45 és 85 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will evaluate whether personalized intermittent theta burst stimulation (iTBS), a form of noninvasive transcranial magnetic stimulation, can safely improve cognitive function in people with cognitive impairment related to cerebral small vessel disease.
A teljes eredeti leírásKevesebb
The study will enroll 160 adults aged 45-85 years with mild cognitive impairment or mild vascular dementia related to cerebral small vessel disease. Participants will be randomly assigned in equal numbers to receive active iTBS or sham stimulation. Brain magnetic resonance imaging (MRI) will be used to identify an individualized stimulation target in the left prefrontal cortex. Sham stimulation will mimic the treatment experience without delivering effective magnetic stimulation. Participants and outcome assessors will not know which treatment participants receive.
Treatment will last 24 weeks. Participants will receive four stimulation sessions per day for five consecutive days during the first week, followed by four sessions on one day each week during weeks 2-24. Cognitive assessments will be performed before treatment, during treatment, at the end of treatment, and three months after treatment ends. The main outcome is the change in Montreal Cognitive Assessment (MoCA) score from baseline to week 24. Brain MRI, electroencephalography (EEG), and adverse event monitoring will be used to examine changes in brain function and treatment safety.
A vizsgálat 2 csoportja
- Active Personalized Intermittent Theta Burst StimulationA vizsgált kezelés
Participants will receive active personalized intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex, with the target individualized using resting-state functional MRI and neuronavigation. Treatment will last 24 weeks: four sessions per day for five consecutive days in week 1, followed by four sessions on one treatment day each week during weeks 2-24. Each session will deliver 1,800 pulses at 80-100% of the resting motor threshold, adjusted according to tolerability, with 50-60 minutes between sessions.
- Sham Personalized Intermittent Theta Burst StimulationSzínlelt kezelés, összehasonlításként
Participants will receive sham stimulation at the individualized left dorsolateral prefrontal cortex target using a dedicated sham coil or sham mode. Sham stimulation will mimic the sounds, vibration, and procedures of active treatment without delivering effective magnetic stimulation. The schedule will match the active group: four sessions per day for five consecutive days in week 1, followed by four sessions on one treatment day each week during weeks 2-24, with 50-60 minutes between sessions.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease: A Randomized, Double-Blind, Sham-Controlled Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07891650: ki vehet részt
- A regiszteradat frissítve
- 2026. október 23.